Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of satralizumab in Neuromyelitis Optica Spectrum Disorder has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Satralizumab (satralizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neuromyelitis Optica Spectrum Disorder | Phase 3 | Status: COMPLETED | Results posted: 2024-12-27